



PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Jane A. Walker February 20, 2004
Jane A. Walker Date

Serial No: 10/681,431
Filed: October 8, 2003
Applicant: Moore
Title: N-Desmethyl Levomepromazine
Art Unit: 1714
Conf. No.: 7143
Examiner: Unknown
Atty Dkt: XANO-33

Cincinnati, Ohio 45202

February 20, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of candor and good faith which is imposed by Rule 56 (37 C.F.R. §1.56), the art listed on the attached form PTO-1449 is called to the attention of the U.S. Patent and Trademark Office in connection with the above identified patent application. Copies of the cited references are provided. No representation is made that the cited art is the only art or that the cited art represents the best art.


The Examiner is urged to consider the cited references and to make an independent decision with respect to their materiality.

Applicant does not believe there is any fee due with this submission.

Should any fees or surcharges be deemed necessary, Examiner has authorization to charge fees or credit any overpayment to Deposit Account No. 23-3000. The Examiner is invited to telephone the undersigned attorney if there are any questions or issues.

Respectfully submitted,


WOOD, HERRON & EVANS, L.L.P.

A handwritten signature in cursive script, reading "Beverly A. Lyman". The signature is written in dark ink and is positioned above a horizontal line.

Beverly A. Lyman
Reg. No. 41,961

2700 Carew Tower
Cincinnati OH 45202
(513) 241-2324
(513) 421-7269 facsimile

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Keith Moore			
(37 CFR 1.98(b))				FILING DATE October 8, 2003		GROUP 1714	



U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)	
	A.L	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)	
A.R	Dahl, Svein G., <u>Pharmacokinetics of methotrimeprazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442
A.S	Dahl, Svein, G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40
A.T	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotrimeprazine and Two of Its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Keith Moore			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE October 8, 2003		GROUP 1714	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	Gennaro, Alfonso R, Ed., <u>Chapter 45 Oral Solid Dosage Forms</u> , Remington: The Science and Practice of Pharmacy, 20th Edition, 2000, Mack Publishing Co., PA, pp.878-893					
	B.S	Gibson, Ed., <u>Pharmaceutical Preformulation and Formulation</u> , IHS Health Group, Englewood CO, 2001 pp. 331-354, 379-458					
	B.T	Hals, PA et al., <u>Metabolism of levomepromazine in man</u> , European Journal of Drug Metabolism and Pharmacokinetics, 1995; 20:61-71					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Keith Moore			
(Use several sheets if necessary)				FILING DATE October 8, 2003	GROUP 1714		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	C.L						
	C.M						
	C.N						
	C.O						
	C.P						
	C.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	C.R	Sztruhar, I et al., <u>Liquid chromatographic resolution of the enantiomers of psychotropic drug levomepromazine (methotrimeprazine) with beta-cyclodextrin-bonded chiral stationary phase</u> , Journal of Pharmaceutical & Biomedical Analyses, 1993; 3:263-266					
	C.S						
	C.T						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							